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ABSTRACT 
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder caused by mutations in the NF2 
gene and predisposing to the development of nervous system. Identification of germline mutations is 
essential to provide appropriate genetic counselling in NF2 patients, but it represents an extremely 
challenging task, as the vast majority of mutations are unique and spread over the entire coding 
sequence. Moreover, about 30% of “de novo” patients are indeed mosaic and direct sequencing can 
undetect mutated alleles present in a minority of cells. As most screening techniques do not meet the 
requirements for efficient NF2 testing, we have developed a semi-automated denaturing high-
performance liquid chromatography (DHPLC) method for point mutation detection combined with a 
MLPA approach to screen for gene rearrangements. In addition, we have evaluated high-resolution 
melting analysis (HRMA) as a exon scanning procedure to identify point mutations in the NF2 gene.  
The results obtained in 92 NF2 patients expand the NF2 mutational spectrum and indicate DHPLC and 
HRMA as good systems to screen for point mutations in diseases with a heterogeneous spectrum of 
alterations. 
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INTRODUCTION 
 
Neurofibromatosis type 2 (NF2; MIM 101000) is an autosomal dominant cancer syndrome that 
predisposes to the development of nervous system tumours (Evans et al., 1992). Bilateral vestibular 
schwannomas are pathognomonic of the disorder; furthermore, schwannomas at other locations, 
meningiomas, ependymomas and juvenile posterior subcapsular lenticular opacities are often 
associated with the disease (Evans et al., 1992; Parry et al., 1994; Mautner et al., 1996). About half of 
NF2 patients have no family history of the disease, representing de novo mutations.  
The disease is caused by mutations in the NF2 tumour-suppressor gene, located in 22q12 (Trofatter et 
al., 1993; Rouleau et al., 1993). Since its identification, different germline mutations have been found 
in up to 91% of NF2 patients with a positive family history using exon-scanning-based methods and 
Multiplex Ligation-dependant Probe Amplification (MLPA) to detect genomic rearrangements (Kluwe 
et al., 2005; Evans et al., 2007). Somatic mosaicism has been found in 25-33% of “de novo” NF2 
patients (Kluwe et al., 2003; Moyhuddin et al., 2003; Evans et al., 2007). Somatic mosaicism may be 
even more common in sporadic NF2 patients with mild phenotyp s, resulting from small proportions of 
cells harbouring mutant NF2 alleles: it has been estimated that 60% of sporadic cases with unilateral 
vestibular schwannoma at presentation might indeed be mosaics (Evans et al., 2007).
Since the vast majority of mutations spread over the entire coding sequence, analysis of the NF2 gene 
has been commonly carried out  with PCR-SSCP as pre-screening method, followed by DNA sequence 
analysis of amplicons that show aberrant band shift. Although this strategy is effective; however, 
turnaround time is relatively long and the limited sensitivity of SSCP does not allow detection of all 
point mutations. The use of direct sequencing as diagnostic tool is reserved to familial NF2 patients, 
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since it has been shown that this approach does not have a 100% sensitivity in mosaic patients, 
especially in cases with low proportion of  mutated cells (Jones et al., 2001). 
To overcome problems deriving from the limited sensitivity of SSCP and other screening techniques, 
denaturing high performance liquid chromatography (DHPLC) (Underhill et al., 1997) was developed 
as a suitable mutation scanning method in a large number of single-locus disease genes (Liu et al., 
1998; Wu et al., 2001; Marsh et al., 2001; Hegde et al., 2005). DHPLC is a semi-automatic method, 
that entails limited post-PCR manipulation; it requires heteroduplex formation and need an accurate 
optimization of running setting prior to chromatography in order to predict conditions for each PCR 
product. The method allows identification of sequence variants through characteristic peak patterns and  
shows many advantages including high sensitivity, specificity and  throughput.  However, DHPLC 
requires the avalilability of  dedicated and  expensive instrumentation.  
Recently, high-resolution melting analysis (HRMA) has been described as a new and highly sensitive 
mutation scanning method to identify point mutations in an amplicon without the need for gel or 
column separation or labeled oligonucleotides (Wittwer 2003; Liew et al., 2004; Reed et al., 2007). In 
this technique PCR is performed in the presence of saturating concentrations of double-stranded DNA 
binding dyes and then amplicons are submitted to high resolution melting analysis monitoring the 
fluorescence across a defined temperature range (Reed and Wittwer 2004). Data acquisition generates a 
change in melting curve shape (Graham et al., 2005) that can be used to identify the presence of 
sequence variation within the amplicon. HRMA has been shown to have near 100% analytical 
sensitivity and specificity when used on products up to 400 base pairs in length (Chou et al., 2005; 
Margraf et al., 2006; Krypuy et al., 2006). HRMA was already used to identified germline and somatic 
point mutations (Kemerson et al., 2007; Margraf et al., 2007; Pal et al., 2007; Dobrowolski et al., 2007; 
Krypuy et al., 2007; Takano et al., 2007).   
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In the present study, we evaluated DHPLC and HRMA-based approach for point mutation scanning of 
NF2 gene.  
 
MATERIALS AND METHODS 
 
Patients and DNA samples  
In the present study DHPLC and HRMA were used to evaluate 92 patients from 92 unrelated Italian 
probands who had been diagnosed with NF2 based on the presence of bilateral vestibular 
schwannomas. Sixteen NF2 patients in whom a pathogenic mutation had been identified by PCR-SSCP 
and characterized by cycle sequencing, were used as positive controls for DHPLC and HRMA (Table 
1). The second group included 76 cases sporadic patients in which PCR-SSCP and Multiplex Ligation-
dependant Probe Amplification (MLPA) (MRC Holland, Amsterdam, The Netherlands), did not reveal 
single point mutations or genomic rearrangements in NF2 gene. High molecular weight genomic DNA 
was extracted by standard phenol/chloroform method from blood samples collected from patients, 
following provision of informed consent.   
Primers and PCR Conditions 
Mutation scanning of NF2 gene requires the analysis of 15 exons, including intron /exon junctions.  
Genomic DNA was amplified using the intronic primer sets reported in Table 2.  For DHPLC analysis, 
PCR reactions were performed in 30 µl, containing 1X PCR buffer (Applied Biosystems, Milan, Italy), 
200 mM of each dNTP, 2mM MgCl2, specific primers, 0.75 U TaqGold DNA polymerase (Applied 
Biosystems) and 50 ng of genomic DNA.  
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DHPLC Analysis 
DHPLC was performed using the WAVEs DNA Fragment Analysis System (Transgenomic, San Jose, 
CA). The PCR products were denatured at 95°C for 3 min, followed by gradual reannealing for 30 min 
with a temperature ramp of  11°C/min to optimize the formation of heteroduplexes and homoduplexes. 
Five µl were applied to a preheated C18 reversed-phase column of nonporous poly(styrene-divinyl-
benzene) particles (DNA-Sep; Transgenomic). DNA was eluted within 2.5 min at a flow rate of 0.9 
ml/min using a linear acetonitrile gradient from 52% to 67% buffer B (0.1M triethylammonium acetate 
[TEAA]; 25% acetonitrile) at the appropriate denaturing temperature. The temperature for heteroduplex 
detection was determined using WAVEMAKER software (Transgenomic), based on the melting 
profiles of the 15 NF2 amplicons (Table 2). The predicted temperature was optimized by testing 
specimens of wild-type DNA and different positive controls. Regeneration of the column was achieved 
by washing with 100% buffer B for 30 sec followed by an equilibration time of 2 min. DNA elution 
was observed online at 260 nm. 
 
High-Resolution Melting Analysis 
 
DNA samples were amplified with the same primers and  PCR conditions used for DHPLC analysis.  
For HRMA, PCR was performed in 20 µL with 50 µM Syto9 (Invitrogen Corp., Carlsbad, CA) as 
intercalating dye. Amplified products were denaturated at 95°C for 1 min and then rapidly cooled to 
40°C for 1 min in order to facilitate heteroduplex formation. HRMA was then performed on a Rotor 
Gene 6000 Instrument (Corbett Research, Sydney, Australia). Melt curve data for each PCR product 
were acquired in a wide temperature range (75°C to 95°C), at a ramping rate of 0.1°C/sec. Results were 
analyzed as fluorescence versus temperature graphs as previously described (Krypuy M. et al., 2006). 
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DNA sequencing 
All cases that exhibited an abnormal melting curve at HRMA and/or aberrant elution profile on  
DHPLC chromatograms, were subjected to sequence analysis. PCR products were purified using a 
QIAquick PCR Purification kit (Qiagen Inc., Germany) and then subjected to cycle sequencing in both 
forward and reverse directions using a BigDye Terminator Cycle Sequencing version 3.1 kit (Applied 
Biosystems) according to the manufacturer’s instructions. The products from each reaction were 
analyzed on an ABI PRISM 310 Genetic Analyser (Applied Biosystems, Milan, Italy). 
Mutation nomenclature follows the Human Genome Variation Society (URL: 
http://www.hgvs.org/mutnomen/) recommendations. The DNA mutation numbering is based on the  
NF2 cDNA sequences (GenBank accession number NM_181832.1) with the A of the ATG translation-
initiation codon numbered as + 1. Amino acid numbering starts with the translation initiator methionine 
as +1. 
 
RESULTS 
Analytical sensitivity and specificity of HRMA were firstly validated on a series of  16 DNA samples 
with previously identified NF2 mutations, detected by PCR-SSCP and characterized by cycle 
sequencing. Exons harbouring these mutations were specifically targeted for screening by DHPLC and 
HRMA. Both methods showed a 100% concordance for the  identification of all DNA alterations 
(Table 1). All samples were distinguishable by significant differences in the melt curves and DHPLC 
traces of the amplified DNA samples when compared to wild-type DNA (Figure1). 
To evaluate the diagnostic sensitivity of DHPLC and HRMA analyses and their ability to identify 
mosaicism in DNA samples, compared to direct sequencing, we performed serial dilutions of a wild-
type DNA with genomic DNA deriving from non-mosaic NF2 patients carring the following mutations: 
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c.997C>T  (exon 10), IVS14+2T>C, IVS15+1G>C. Dilutions were made corresponding to a 1:1, 1:4, 
1:10, 1:20, 1:100 and 1:1000 ratio of patient:normal DNA, respectively. In our experimental 
conditions, DHPLC and HRMA were able to detect the c.997C>T  and IVS15+1G>C mutations until a 
dilution 1:100 in which the mutant allele was present at 0.25% relative to the normal allele (Figure 2) 
while the IVS14+2T>C mutation was detectable until 1:20 dilution (1.25% of the mutant allele). Direct 
sequencing detected the c.997C>T  and IVS15+1G>C mutations until dilution 1:4  (6.25% of the 
mutant allele) and the IVS14+2T>C alteration until dilution 1:1 (25% of the mutant allele) (Figure 3). 
To test “in vivo” this capability, DHPLC and HRMA were performed in one previously described 
mosaic patient with an inactivating mutation in NF2 gene (Sestini et al., 2000). In this patient, both 
techniques indicated an abnormal profile related to the presence of a c.1416delC mutation in exon 13 
(Figure 4). 
Subsequently, we analysed 76 NF2 samples for which previous mutation screening by PCR-SSCP had 
not revealed sequence changes. As reported in Figure 5, we identified 7 samples with abnormal 
DHPLC peaks and showing differences in the melt curves in HRMA. Sequencing analysis of the 
involved exons demonstrated in all cases the presence of 6 different point mutations. These six 
different mutation included two nonsense (c.592C>T, p.R198X and c.1090A>T, p.K364X involving 
exon 6 and exon 11 respectively), one missense (c.447G>C, p.K149N in exon 4), one frameshift 
(c278delCCTT in exon 3) and two splice site mutations (IVS3+3A>C and IVS7 -1G>T). 
 
DISCUSSION 
 
High sensitivity in detection of DNA sequence variations is essential for mutation analysis in genetic 
diseases. A wide range of methodologies for exon scanning have been proposed to select samples with 
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aberrant profiles to be submitted to DNA sequencing, with the aim to reduce laboratory costs and 
analysis time. 
DHPLC has been extensively applied to single nucleotide polymorphism analysis and mutational 
screening for different disease associated genes (Gross et al., 1999; Nickerson et al., 2000; Dobson-
Stone et al., 2000; Jones et al., 2000; Jones et al., 2001). This methodology allows a rapid separation 
and visualization of homo- and heteroduplex DNA targets by using a reverse-phase liquid 
chromatography system. Maximal sensitivity in the heteroduplex detection is obtained maintaining the 
HPLC column at an optimal melting temperature that allows partial strand denaturation in the presence 
of a single base-pair mismatching.  
Recently, HRMA has been proposed as an alternative scanning method to identify changes in DNA 
sequence using melting-curve analysis of the amplicons. This technique allows characterization of the 
DNA samples according to their dissociation behaviour in transition from double stranded to single 
stranded DNA with increasing temperature. As reported for DHPLC, also HRMA identifies 
heteroduplexes by their lower thermal stability (Reed et al., 2004). However, unlike DHPLC, melting 
analysis scans through a wide range of temperatures rather than depending on a specific temperature, a 
feature that normally requires time-consuming optimization for each amplicon to be analyzed.  
HRMA relies on the use of fluorescent dsDNA-binding dyes that can be added directly to the PCR mix 
at saturating concentrations without inhibiting amplification (Wittwer and Reed 2003). This allows the 
precise monitoring of very low changes in fluorescence, caused by the release of a intercalating dyes 
consequent to the increase of temperature (Liew et al., 2004). Thus, single base changes can be readily 
identified as a significant differences in the melting curves of DNA amplicons (Reed et al., 2007). 
Consequently, HRMA results to be a closed-tube mutation screening method, that can be performed 
immediately after the amplification and does not require post-PCR handling or separation steps. These 
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features make HRMA particularly suitable for medium to high-throughput applications (Dobrowolski 
et al., 2007; Margraf 2006; Montgomery et al., 2007) .  
In this study we compared for the first time DHPLC and HRMA for mutation scanning of the NF2 gene 
in two groups of patients. The first one, included patients with a known pathogenetic mutation. The 
second group included 76 NF2 sporadic patients where PCR-SSCP screening was unable to reveal 
point mutations and MLPA analysis excluded genomic rearrangements. In both groups, HRMA results 
were compared in blind with those obtained with DHPLC. Our results indicated that both DHPLC and 
HRMA show a 100% sensitivity in detecting mutations previously characterised by PCR-SSCP, 
without any false positive samples. In addition, both DHPLC and HRMA detected 7 new samples with 
abnormal peaks at DHPLC analysis and anomalous melting profile at HRMA. Sequencing analysis 
revealed mutations in the involved exons including nonsense, missense, frameshift and splice site 
mutations. 
Another very important aspect in the evaluation of methods for NF2 mutational scanning is their 
capability to detect mosaicism. The identification of somatic mosaicism in a genetic syndrome is 
clinically relevant and this information has important implications for genetic counselling. According 
to our data, DHPLC and HRMA, performed on serial diluition of mutated:normal DNA samples, were 
able to detect the presence of 1.25% - 0.25% mutated alleles, a theorical threshold able to identify 
patients with a very low percentage of mutated cells in blood; this percentage is well under the direct 
sequencing threshold of detection .  
In summary, in our experience that both DHPLC and HRMA are reliable techniques for mutation 
scanning in NF2 gene. However, due to its simplicity,  rapidity, and  lower costs, together with its high 
sensitivity in detecting germline mutations and mosaicisms and to the absolute concordance with 
DHPLC results, we propose that HRMA could be used as a diagnostic screening technique for NF2 
patients.  
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Table 1: Known mutations in the NF2 gene detected with DHPLC and HRMA. 
 MUTATION 
EXON 1 
 
c.71-72insT 
EXON 2 
c.169C>T  p.R57X 
c.169C>T  p.R57X 
c.169C>T  p.R57X 
c.169C>T  p.R57X 
IVS2+2T>C 
EXON 5 
 
c.463delCCinsT 
EXON 7 
 
c.656T>A p.V219E 
c.663C>G p.Y221X 
EXON 8 
 
c.773G>A p.W257X 
EXON 10 
 
c.997C>T  p.Q333X 
EXON 12 
 
c.1279G>T  p.E427X 
EXON 13 
 
c.1416delC 
c.1396C>T  p.R466X 
EXON 14 
 
IVS14+2T>C 
EXON 15 
 
IVS15+1G>C 
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Table 2: Primers for PCR amplification of NF2 gene and temperatures for heteroduplex detection in DHPLC analysis
PRIMER SEQUENCE
EXON PRODUCT
SIZE
(bp) FORWARD REVERSE
Tm PCR* DHPLC ANALYSIS**
1 235 5’-GGG CTA AAG GGC TCA GAG TG-3’ 5’-AAC CTC TCG AGC TTC CAC CT-3’ 59°C 64.5°C
2 265 5’-CCT GAG AGT GGA GAG TGC AG-3’ 5’-GGG AAA AAC TGG AAA GCT CA-3’ 62°C 58.5°C - 60.9°C
3 241 5’-TGA GGG TAG CAC AGG AGG AA-3’ 5’-CAA CTC TGC AAC CAC TCC TG-3’ 57°C 58.7°C
4 237 5’-CAC AGA GTA TCA TGT CTC CCT TG-3’ 5’-CAC TTT CTG GGG CAA GTC TC-3’ 58°C 57.5°C - 58.3°C - 61.2°C
5 188 5’-AGC TGG GAG GGA ATG AGA TT-3’ 5’-TCC TTC AAG TCC TTT GGT TAG C-3’ 59°C 56.5°C - 59.5°C
6 192 5’-AAA AGT GGC AAA CAA TAC CAA A-3’ 5’-AAG CCC ATA AAG GAA TGT AAA CC-3’ 61°C 54.7°C - 59.5°C
7 177 5’-GCTCTCCACCCATCTCACTT-3’ 5’-TTT AGC AGT CTG GCC CTC AC-3’ 59°C 59.7°C - 60.6°C
8 258 5’-TGC CAG ATT CTT TGG AAG GT-3’ 5’-GCA GAC AGG GAA AGA TCT GC-3’ 57°C 58.8°C - 60.5°C
9 248 5’-GGT AAC ATT CCA GGC TGT CG-3’ 5’-GCG CCA AGT GAG ATA CCA TT-3’ 59°C 55.9°C - 56.5°C
10 234 5’-TAG TGG GCC AGT AGG CAG TG-3’ 5’-GCC AGG ACT GAC CAC ACA G-3’ 60°C 57.2°C - 58.8°C - 60.0°C
11 212 5’- CTC GAG CCC TGT GAT TCA A -3’ 5’-AGT CCC CAA GTA GCC TCC TG-3’ 62°C 60.5°C - 61.8°C - -63.0°C
12 284 5’- CCC ACT TCA GCT AAG AGC AC -3’ 5’-CTC CTC GCC AGT CTG GTG-3’ 64°C 62.1°C - 63.8°C
13 227 5’- GGT GTC TTT TCC TGC TAC CT -3’ 5’-ACC ACT ACA AGA GAA AGG AGG G-3’ 60°C 60.7°C - 61.9°C - 64.5°C
14 246 5’- AGG ATC GGT TGT CAA CAC AG -3’ 5’-GGC CCC AAT CAC TCA GTC TA-3’ 61°C 58.9°C - 60.0°C
15 255 5’- TGT CTC ACT GTC TGC CCA AG--3’ 5’-TGG TCC TGA TCA GCA AAA A-3’ 60°C 56.6°C - 60.5°C
* Annealing temperature for PCR amplification
**Optimum temperatures for DHPLC analysis were empirically determined using the predicted fragment melting profile generated by WAVEMAKER software.
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Figure legends 
Figure 1 
DHPLC chromatograms and HRMA melting profiles for known NF2 gene mutations in exons 2, 7, 12 
14, 15. The arrows indicates variant elution profiles and change in melting curve shape. 
MUT – mutant 
 
Figure 2 
Evaluation of the sensitivity in detecting mosaicism of DHPLC and HRMA. Serial dilutions of a wild-
type DNA with genomic DNA carring a c.997C>T mutation in exon 10, deriving from a non-mosaic 
NF2 patient were prepared. Dilutions corresponding to a 1:1, 1:4, 1:10, 1:20, 1:100 and 1:1000 ratio of 
patient : normal DNA were amplified in PCR and analysed by DHPLC and HRMA. 
A) DHPLC chromatograms showing the double peak corresponding to the mutation in dilutions 
1:1, 1:4, 1:10, 1:20, 1:100. 
B) HRMA difference plots of  patient : normal DNA dilutions. All dilutions were compared to the 
median wild-type control sample to produce the plot. The mutated allele was easily detectable 
in all the dilution tested except 1:1000. 
 
Figure 3 
Evaluation of the sensitivity in detecting mosaicism of HRMA and direct sequencing. HRMA 
difference plots (on the left) and direct sequencing (on the right) of  patient : normal DNA dilutions. 
A) Mutation IVS15+1G>C. The mutated allele was detectable, until dilution 1:100 and 1:20 
respectively by  HRMA and direct sequencing. 
B) Mutation IVS14+2T>C. The mutated allele was detectable, until dilution 1:20 and 1:1 
respectively by  HRMA and direct sequencing. 
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Figure 4  
DHPLC chromatograms and HRMA melting curves representative of the mutation detected in a mosaic 
patient carrying a mutation in NF2 exon 13, namely c.1416delC.  
 
Figure 5 
DHPLC (left) and HRMA (right) profiles of the mutations lost at SSCP analysis. 
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Table 1: Known mutations in the NF2 gene detected with DHPLC and HRMA.
MUTATION
EXON 1 c.71-72insT
EXON 2
c.169C>T  p.R57X
c.169C>T  p.R57X
c.169C>T  p.R57X
c.169C>T  p.R57X
IVS2+2T>C
EXON 5 c.463delCCinsT
EXON 7 c.656T>A p.V219E
c.663C>G p.Y221X
EXON 8 c.773G>A p.W257X
EXON 10 c.997C>T  p.Q333X
EXON 12 c.1279G>T  p.E427X
EXON 13 c.1416delC
c.1396C>T  p.R466X
EXON 14 IVS14+2T>C
EXON 15 IVS15+1G>C
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Table 2: Primers for PCR amplification of NF2 gene and temperatures for heteroduplex detection in DHPLC analysis
PRIMER SEQUENCE
EXON PRODUCT  
SIZE 
(bp) FORWARD REVERSE
Tm PCR* DHPLC ANALYSIS**
1 235 5’-GGG CTA AAG GGC TCA GAG  TG-3’ 5’-AAC CTC TCG AGC TTC CAC CT-3’ 59°C 64.5°C
2 265 5’-CCT GAG AGT GGA GAG TGC AG-3’ 5’-GGG AAA AAC TGG AAA GCT CA-3’ 62°C 58.5°C - 60.9°C
3 241 5’-TGA GGG TAG CAC AGG AGG AA-3’ 5’-CAA CTC TGC AAC CAC TCC TG-3’ 57°C 58.7°C
4 237 5’-CAC AGA GTA TCA TGT CTC CCT TG-3’ 5’-CAC TTT CTG GGG CAA GTC TC-3’ 58°C 57.5°C - 58.3°C - 61.2°C
5 188 5’-AGC TGG GAG GGA ATG AGA TT-3’ 5’-TCC TTC AAG TCC TTT GGT TAG C-3’ 59°C 56.5°C - 59.5°C
6 192 5’-AAA AGT GGC AAA CAA TAC CAA A-3’ 5’-AAG CCC ATA AAG GAA TGT AAA CC-3’ 61°C 54.7°C - 59.5°C
7 177 5’-GCTCTCCACCCATCTCACTT-3’ 5’-TTT AGC AGT CTG GCC CTC AC-3’ 59°C 59.7°C - 60.6°C
8 258 5’-TGC CAG ATT CTT TGG AAG GT-3’ 5’-GCA GAC AGG GAA AGA TCT GC-3’ 57°C 58.8°C - 60.5°C
9 248 5’-GGT AAC ATT CCA GGC TGT CG-3’ 5’-GCG CCA AGT GAG ATA CCA TT-3’ 59°C 55.9°C - 56.5°C
10 234 5’-TAG TGG GCC AGT AGG CAG TG-3’ 5’-GCC AGG ACT GAC CAC ACA G-3’ 60°C 57.2°C - 58.8°C - 60.0°C
11 212 5’- CTC GAG CCC TGT GAT TCA A -3’ 5’-AGT CCC CAA GTA GCC TCC TG-3’ 62°C 60.5°C - 61.8°C - -63.0°C
12 284 5’- CCC ACT TCA GCT AAG AGC AC -3’ 5’-CTC CTC GCC AGT CTG GTG-3’ 64°C 62.1°C - 63.8°C
13 227 5’- GGT GTC TTT TCC TGC TAC CT -3’ 5’-ACC ACT ACA AGA GAA AGG AGG G-3’ 60°C 60.7°C - 61.9°C - 64.5°C
14 246 5’- AGG ATC GGT TGT CAA CAC AG -3’ 5’-GGC CCC AAT CAC TCA GTC TA-3’ 61°C 58.9°C - 60.0°C
15 255 5’- TGT CTC ACT GTC TGC CCA AG--3’ 5’-TGG TCC TGA TCA GCA AAA A-3’ 60°C 56.6°C - 60.5°C
*  Annealing temperature for PCR amplification 
**Optimum temperatures for DHPLC analysis were empirically determined using the predicted fragment melting profile generated by WAVEMAKER software.
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